Skip to main
IBIO

iBio (IBIO) Stock Forecast & Price Target

iBio (IBIO) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

iBio Inc's innovative approach to utilizing Artificial Intelligence in the development of precision antibodies positions it favorably within the biotechnology sector, as it aims to reduce drug failures and accelerate development timelines. The company’s expertise in epitope-steering and monoclonal antibody optimization enhances its product candidates, which are designed to maintain improved safety profiles and manufacturability. Additionally, promising early results from preclinical models, such as the significant reduction in food intake seen with its amylin receptor agonist antibody, highlight the potential of iBio's technology to make substantial advancements in treating metabolic diseases.

Bears say

iBio Inc faces significant risks due to the potential for ongoing development in treatment methods that may render its therapies obsolete or non-competitive. There is also considerable uncertainty surrounding the outcomes of current and future clinical studies, which could negatively impact investor sentiment if the company fails to meet clinical endpoints. Furthermore, the company's intellectual property may not provide adequate protection, adding another layer of vulnerability to its competitive positioning and overall financial stability.

iBio (IBIO) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iBio (IBIO) Forecast

Analysts have given iBio (IBIO) a Buy based on their latest research and market trends.

According to 4 analysts, iBio (IBIO) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iBio (IBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.